Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 870-875

  Wiegering, Verena ^a   Frank, Jana ^a   Freudenberg, Sandra ^a   Morbach, Henner ^b,c   Schlegel, Paul G ^a   Eyrich, Matthias ^a   Winkler, Beate ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; B lymphocyte subsets; Immune reconstitution; Pediatric patients; T lymphocyte subsets

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; DAUNORUBICIN; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; HUMAN; IMMUNITY; LYMPHOCYTE DEPLETION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; FLOW CYTOMETRY; FOLLOW UP; IMMUNOLOGY; IMMUNOPHENOTYPING; INFANT; METABOLISM; NATURAL KILLER CELL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INFANT; KILLER CELLS, NATURAL; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84904300583     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.816423     Document Type: Article

References (28)

1. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia.Leukemia 2000;14:2193-2194. (Pubitemid 32043589)
2. Eden T, Pieters R, Richards S. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia-an individual patient data meta-analysis involving 5, 659 children. Br J Haematol 2010; 149:722-733.
3. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
4. Wehinger H, Karitzky D. [T and B lymphocytes before, during, and after cytostatic therapy of acute lymphoblastic leukemia (ALL) in children (author's transl)].KlinPadiatr 1977;189:234-241.
5. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4 + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143-149.
6. Haining WN, Cardoso AA, Keczkemethy HL, et al. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol 2005; 33: 286-294. (Pubitemid 40261310)
7. Eyrich M, Wiegering V, Lim A, et al. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia-a prospective study of 20 paediatric patients. Br J Haematol 2009; 147: 360-370.
8. van Tilburg CM, van Gent R, Bierings MB, et al. Immune reconstitution in children following chemotherapy for haemato- logical malignancies: a long-term follow-up. Br J Haematol 2011;152: 201-210.
9. van Tilburg CM, van der Velden VH, Sanders EA, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition. Leuk Res 2011; 35: 484-491.
10. Ek T, Mellander L, Andersson B, et al. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005;44:461-468. (Pubitemid 40614494)
11. LehrnbecherT, Schubert R, BehlM, et al. Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia. Br J Haematol 2009; 147: 700-705.
12. Aquino VM, Douek DC, Berryman B, et al. Evaluation of thymic output by measurement of T-cell-receptor gene rearrangement excisional circles (TREC) in patients who have received fludarabine. Leuk Lymphoma 2003;44:343-348. (Pubitemid 36113873)
13. van Wering ER, van der Linden-Schrever BE, Szczepanski T, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol 2000; 110: 139-146. (Pubitemid 30627499)
14. vanLochem EG, Wiegers YM, van den Beemd R, et al. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia 2000; 14: 688-695. (Pubitemid 30195461)
15. LeBien TW, Tedder TF. B lymphocytes: how they develop and function.Blood 2008;112: 1570-1580.
16. Morbach H, Eichhorn EM, Liese JG, et al. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol 2010; 162: 271-279.
17. AlankoS, PelliniemiTT, SalmiTT.RecoveryofbloodB-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 1992; 69: 1481-1486.
18. Nilsson A, De Milito A, Engstrom P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002; 109: e91.
19. KosmidisS, BakaM, BouhoutsouD, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer 2008;50: 528-532.
20. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-2386. (Pubitemid 44204997)
21. van Tilburg CM, Sanders EA, Rovers MM, et al. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia 2006;20: 1717-1722. (Pubitemid 44574983)
22. Patel SR, Ortin M, Cohen BJ, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007; 44: 635-642.
23. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-14.
24. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity.Curr Opin Immunol 2008; 20: 632-638.
25. Wiegering V, Girschick HJ, Morbach H.B-cell pathology in juvenile idiopathic arthritis. Arthritis 2010;2010:759868.
26. Tangye SG, Bryant VL, Cuss AK, et al. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305-317. (Pubitemid 44287555)
27. Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012;188:497-503.
28. El-Chennawi FA, Al-Tonbary YA, Mossad YM, et al. Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection. Hematology 2008; 13: 203-209.